# Title: A *Trypanosoma cruzi* Trans-Sialidase Peptide Demonstrates High Serological Prevalence Among Infected Populations Across Endemic Regions of Latin America

**Authors:** Hannah M. Kortbawi[1,2]†, Ryan J. Marczak[3,4]†, Jayant V. Rajan[1‡], Nash L. Bulaong[5], John E. Pak[5], Wesley Wu[5], Grace Wang[5], Anthea Mitchell[5], Aditi Saxena[5§], Aditi Maheshwari[3,4||], Charles J. Fleischmann[4¶], Emily A. Kelly[4], Evan Teal[4], Rebecca L. Townsend[6], Susan L. Stramer[6††], Emi E. Okamoto[7#], Jacqueline E. Sherbuk[7]**, Eva H. Clark[8,9], Robert H. Gilman[10], Rony Colanzi[11], Efstathios D. Gennatas[3,12], Caryn Bern[3]*, Joseph L. DeRisi[1,5]*, Jeffrey D. Whitman[4*]

**Affiliations:**

[1]Department of Biochemistry and Biophysics, University of California San Francisco; San Francisco, CA, USA.

[2]Medical Scientist Training Program, University of California San Francisco; San Francisco, CA, USA.

[3]Department of Epidemiology and Biostatistics, University of California San Francisco; San Francisco, CA, USA.

[4]Department of Laboratory Medicine, University of California, San Francisco; San Francisco, CA, USA.

[5]Chan Zuckerberg Biohub San Francisco; San Francisco, CA, USA.

[6]Scientific Affairs, American Red Cross; Gaithersburg, MD, USA.

[7]New York University School of Medicine; New York, NY, USA.

[8]Section of Infectious Diseases, Department of Medicine, Baylor College of Medicine; Houston, TX, USA.

[9]Division of Tropical Medicine, Department of Pediatrics, Baylor College of Medicine; Houston, TX, USA.

[10]Johns Hopkins University Bloomberg School of Public Health; Baltimore, MD, USA.

[11]Universidad Catolica Boliviana; Santa Cruz, Plurinational State of Bolivia.

[12]Department of Medicine, University of California San Francisco; San Francisco, CA, USA.

†, Authors contributed equally.

‡, JVR current affiliation, Current affiliation Pfizer, Inc; Collegeville, PA, USA.

§, AS current affiliation, Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health; Boston, MA, USA.

||, AM current affiliation, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

¶, CJF current affiliation, Noorda College of Osteopathic Medicine; Provo, UT, USA.

#, EEO current affiliation, Independent Consultant.

**, JES current affiliation, University of South Florida; Tampa, FL, USA.

††, SLS current affiliation, Infectious Disease Consultant, North Potomac, MD

*, Corresponding authors, caryn.bern2@ucsf.edu, joe@derisilab.ucsf.edu, jeffrey.whitman@ucsf.edu.

**One Sentence Summary:** Phage display immunoprecipitation sequencing (PhIP-seq) designed with a *T. cruzi* whole proteome library reveals a trans-sialidase peptide antigen (TS-2.23) with antibody responses highly prevalent across endemic regions of Latin America.

**Abstract:** Infection by *Trypanosoma cruzi*, the agent of Chagas disease, can irreparably damage the cardiac and gastrointestinal systems during decades of parasite persistence and related inflammation in these tissues. Diagnosis of chronic disease requires confirmation by multiple serological assays due to the imperfect performance of existing clinical tests. Current serology tests utilize antigens discovered over three decades ago with small specimen sets predominantly from South America, and lower test performance has been observed in patients who acquired *T. cruzi* infection in Central America and Mexico. Here, we attempt to address this gap by evaluating antibody responses against the entire *T. cruzi* proteome with phage display immunoprecipitation sequencing comprised of 228,127 47-amino acid peptides. We utilized diverse specimen sets from Mexico, Central America and South America, as well as different stages of cardiac disease severity, from 185 cases and 143 controls. We identified over 1,300 antigenic *T. cruzi* peptides derived from 961 proteins between specimen sets. A total of 67 peptides were reactive in 70% of samples across all regions, and 3 peptide epitopes were enriched in ≥90% of seropositive samples. Of these three, only one antigen, belonging to the trans-sialidase family, has not previously been described as a diagnostic target. Orthogonal validation of this peptide demonstrated increased antibody reactivity for infections originating from Central America. Overall, this study provides proteome-wide identification of seroreactive *T. cruzi* peptides across a large cohort spanning multiple endemic areas and identified a novel trans-sialidase peptide antigen (TS-2.23) with significant potential for translation into diagnostic serological assays.

**Main Text:**

## INTRODUCTION

Chagas disease is caused by infection with the protozoan parasite, *Trypanosoma cruzi*, which is transmitted by triatomine insect vectors. The disease is endemic to the Americas, with vector-borne transmission occurring in suitable ecological zones of Latin America (*1*). In the United States (US), the major disease burden occurs among Latin American immigrant populations exposed in their birth countries, although rare autochthonous infections have been documented in Texas, California, Arizona, Tennessee, Mississippi and other southern states (*2, 3*). Chronic Chagas disease is considered a lifelong infection without treatment. *T. cruzi* can infect many nucleated cell types but causes pathology in the cardiac and gastrointestinal systems. An estimated 20 to 30% of people with chronic Chagas disease develop symptoms of end organ damage after years to decades of infection. Related cardiac presentations include cardiac conduction system deficits, dilated cardiomyopathy, and sudden cardiac death (*4*). Ten percent of infected individuals may develop gastrointestinal dysmotility disorders (*5, 6*). Because this parasite is predominantly intracellular in the chronic phase and symptoms are largely non-

existent or non-specific, detection of anti-*T. cruzi* antibodies in peripheral blood is the most sensitive method for diagnosis and is the only reliable means of screening asymptomatic patients.

The test performance of current Chagas disease serology assays does not have the accuracy (sensitivity or specificity) to effectively diagnose patients by one test alone (*7*). Pan American Health Organization/World Health Organization (PAHO/WHO) guidelines require confirmation by two tests with distinct antigen sources. The indications for *T. cruzi* serology span many areas of healthcare, including clinical diagnosis, blood donor screening, and solid organ or hematopoietic stem cell transplant donor and recipient testing (*8-11*). In practice, securing repeat testing for patients and identifying clinical laboratories that offer more than one serology test can be difficult and time consuming, and ultimately patients may be lost to follow-up. Given the mounting awareness of the need for Chagas disease screening and imperfect test performance, it is clear that the serology assays themselves must be improved to increase the effectiveness of screening and diagnosis efforts.

Recent studies evaluating regionally-diverse Chagas disease populations highlight differential reactivity to commercial *T. cruzi* serology assays between infected populations; with the lowest reactivity in individuals from Mexico, intermediate reactivity from Central America, and the highest reactivity from South America (*12-15*). Up to an estimated 10% loss in sensitivity between infections originating from Mexico compared to South America has been observed depending on the assay used (*12*). Other studies based in endemic areas have documented decreased performance of commercial serological assays in regions of Mexico and Central America, as well as Peru (*16-19*). *T. cruzi* is a genetically diverse parasite, currently classified into six genetic lineages or discrete typing units (DTUs: TcI – TcVI) (*20*), plus a potential seventh, bat-associated genotype (TcBat), most closely related to TcI (*21*). It is hypothesized that host immunological responses and antigenic differences between regional *T. cruzi* strains may be the basis of the differential serological responses. However, the areas with problematically low reactivity to commercial assays are largely found where TcI is predominant, but not all TcI-predominant areas show low reactivity (*22*). Genetic variation is also high within TcI (*23*), suggesting that DTU-level classification is not sufficiently granular to map host immunology to parasite genetics.

The antigens used in current commercial diagnostics originated from a surge of Chagas disease serology research over the last three decades (*24*). These studies tended to rely on screening with sera from high prevalence regions of South America, where TcII/V/VI are predominant; mainly Brazil and Argentina. Since then, more robust techniques for antigen discovery have emerged in the form of high-density peptide microarrays. Recent application of these techniques to Chagas disease have generated additional antigen targets *(25-27)*. However, these studies used pooled sera for determining the initial down selection of antigenic targets for secondary peptide array libraries. Such an approach is unable to discern commonality of antigens across the entire *T. cruzi* proteome among the pooled sera. The antigen targets chosen for follow-on validation in individual specimens were therefore biased towards the highest reactivity antigens within a pool, not necessarily the highest prevalence antigens.

To address these gaps, we employed phage display immunoprecipitation sequencing (PhIP-seq) (*28*) using a synthetic oligonucleotide library with high-density coverage of the *T. cruzi* proteome using 47 amino acid peptides. We performed immunoprecipitation using 185 serology-confirmed cases from geographically diverse regions of Latin America to explicitly represent the genetic diversity of *T. cruzi* antigens across DTUs, as well as varying presentations of Chagas

cardiomyopathy to control for any differences by disease severity. The goal of this study was to employ a next-generation antigen discovery technique to *T. cruzi* and evaluate high-prevalence antigen targets with translational potential for serological diagnostics.

## RESULTS

### Development of *T. cruzi* proteome library

We constructed a T7 phage-display library to display the entire *T. cruzi* CL Brener proteome in 49-amino acid (aa) peptides with a 19-mer overlap in consecutive sequences (*Materials and Methods*, Fig. 1). The library includes 228,127 *T. cruzi* peptides that represent 19,607 proteins. Over 99.6% of the ordered peptides were represented in the final cloned library, with 90% of peptides represented within a 9-fold difference of read counts (Fig. S1).




**Fig. 1. PhIP-seq library design and assay steps.** Phage library displays the proteome of *T. cruzi* in 47-aa peptides with a 19-aa step size on the capsid of T7 phage. The library includes all coding regions of the proteome and splice variants. We performed the PhIP-seq assay by incubating the phage library with human plasma, followed by immunoprecipitation of antibodies in the sample and enrichment of antibody-bound phage through lysis in *E. coli*. We performed two rounds of enrichment and then sequenced the enriched phage to obtain the identity of the immunoprecipitated peptides.

### PhIP-seq identifies antibodies to *T. cruzi* peptides

We performed PhIP-seq on peripheral blood samples from three distinct specimen sets including US blood donors with routine Chagas disease serology screening (BD, $n$=90; $n$=64 seropositive, $n$=26 seronegative), a Chagas disease cardiac biomarker study (CBM, $n$=143; $n$=121 seropositive, $n$=22 seronegative), and independent healthy controls (NYBC, $n$=95). See *Materials and Methods* for a full description of these specimens. The PhIP-seq library contained human GFAP sequences, so a polyclonal anti-GFAP antibody was used as a positive control for immunoprecipitation. Positive control samples were highly enriched for GFAP peptides (Fig. S2). We excluded ten samples from the analysis due to low sequencing read counts; seven seropositive CBM samples, two seronegative CBM study samples, and one NYBC control. In total, 185 cases and 143 controls were included for further data analysis.

We used a conservative analysis approach to identify antibody reactivity to individual *T. cruzi* peptides that were enriched (z-score ≥5) in at least 5% of seropositive patients (Fig. S3). Z-scores were calculated based on the distribution of sequencing reads per 100,000 (RPK) value for a given peptide in seronegative patients, which included endemic region seronegative controls as well as independent seronegative controls from the US. With this approach, 5,638 individual peptides representing 4,001 proteins were enriched in the seropositive CBM samples, and 8,710 peptides representing 5,629 proteins were enriched in the seropositive BD samples.

Between both cohorts, 12,978 antigenic peptides corresponding to 7,373 unique proteins were identified, with an overlap of 1,370 peptides across 961 proteins in both Chagas disease study sets (Fig. S4). A total of 67 and 85 peptides were reactive in at least 70% of samples among the BD samples and CBM samples, respectively. Across both cohorts, 43 of these 70% seroreactivity peptides were shared.

**Significantly enriched *T. cruzi* antigens in seropositive samples**

The antigenic peptides identified across both specimen sets represented 38% of the 19,607-member proteome of *T. cruzi*. Most of these peptides demonstrated no enrichment in seronegative samples (Fig. 2a, b). The median number of enriched Chagas disease-specific peptides in each seropositive sample was higher in the BD specimens compared to the CBM specimens (Fig. 2c), but the mean number of enriched peptides per sample did not significantly differ within cohorts by patient region of origin (BD specimens) or by heart disease stage (CBM specimens) (Kruskall-Wallis, BD $H(2) = 1.77$, $p = 0.41$; CBM $H(3) = 2.49$, $p = 0.48$).

The proteins from which the enriched peptides derive are predominantly expressed in the host phase lifecycle stages of *T. cruzi* (metacyclic trypomastigotes, trypomastigotes, and amastigotes) (*29*) (Fig. 2d). There were relatively fewer seroreactive peptides that corresponded to proteins expressed in the epimastigote form, which only occurs in the gut of the triatomine vector. Examples of host phase-specific proteins that had high antibody reactivity included trans-sialidases and mucin-associated surface proteins.




**Fig. 2. PhIP-seq captures known antigens across the *T. cruzi* life cycle stages.** (**A**,**B**) Heatmap of z-score enrichment over seronegative controls in the (A) blood donor (BD) specimens (n=64 seropositive, n=26 seronegative) and the (B) cardiac biomarker (CBM) specimens (n=114, seropositive; n=18, seronegative; n=95, healthy controls) for seroreactive peptides (rows) with >15% seropositivity within each cohort. Peptides are sorted by protein name and samples are sorted by patient region of origin (n=10, Central America [yellow]; n=13, Mexico [blue]; n=12, South America [light green]; n=1, USA [pink]; n=28, unknown [green]) (A), or cardiac disease stage (n=14 stage A seronegative [magenta]; n=6 stage B seronegative [orange]; n=38 stage A seropositive [magenta]; n=46 stage B seropositive [orange]; n=7 stage C seropositive [light green]; n=23 stage D seropositive [blue]) (B). Protein groups with well-characterized antigens are indicated by labels (Surface antigen, Surface antigen 2 (CA-2); NSP-like, Nucleoporin NSP1-like C-

terminal domain-containing protein; MASP, Mucin-associated surface protein; Mucin, TcMUCII; MAP, Microtubule-associated protein; CCP, Calpain-like cysteine peptidase; 60S, 40S, ribosomal subunit proteins). (**C**) Breadth of antibody reactivity, shown as the number of seroreactive peptides in each person. The dotted red line and number signify the median number of seroreactive peptides in BD and CBM specimen sets. Samples are grouped by geographic region (BD specimens) and heart disease stage (CBM specimens). (**D**) Number of peptides identified as seroreactive in this study that are part of proteins expressed in specific stages of the *T. cruzi* life cycle (Tryp = trypomastigote; Ama = amastigote; Meta = metacyclic trypomastigote; Epi = epimastigote; Multiple = protein is expressed in trypomastigote, amastigote, and/or metacyclic trypomastigote stages). Stage expression analysis shows seroreactive peptides in every host-interfacing lifecycle stage. Stage-specific expression is based on the 'Life cycle proteome (Brazil)' data set from TriTrypDB. Gene IDs for stage-specific proteins were mapped onto the gene IDs that corresponded to seroreactive peptides. (**E**,**F**) Selected known seroreactive antigens are captured by *T. cruzi* PhIP-seq. Neg. is seronegative specimens from the respective specimen sets; Pos. is seropositive specimens from the respective cohorts; NYBC is NYBC US controls. Antibody reactivity to two known antigens (E) Ag2, a nucleoporin protein, and (F) TCE, a 60S ribosomal subunit protein are plotted as reads per 100,000 (RPK). The dotted red line signifies the RPK that corresponds to a z-score cutoff of 5 in the seronegative population of each cohort.

## Identification of high-prevalence *T. cruzi* antigens across Latin America

To identify high-prevalence antigens shared across endemic regions representing different *T. cruzi* DTUs, we first analyzed BD specimens, which included individuals born in Mexico, Central America and South America. We performed two complementary approaches to identify individual antigens with sufficient seroprevalence to have utility for clinical diagnostic assays. First, we used the z-scored, peptide-level data to identify peptides enriched in ≥90% of seropositive BD samples. Second, we used mass univariate analysis to create a ranked list of top antigenic peptides by largest predictor coefficient values. The mass univariate analysis approach models peptide RPK scores based on diagnostic status in our BD specimens. All peptides identified by the z-score approach were also identified as significantly enriched by the mass univariate analysis (Fig. S5). These analyses were then performed on the CBM specimens to evaluate for any differences in high-prevalence antigens by cardiac disease status; none were identified.

These analyses yielded 23 peptides (Table S1), including 20 peptides that all contain the repetitive PFGQAAAGDKPS antigenic sequence, present in a current diagnostic antigen known as Ag 2 (*30, 31*) (Fig. 2e). An additional highly reactive peptide, which contained the antigenic sequence KAAAPKKAAAPQ, has high sequence homology to another known diagnostic antigen, TcE (*32*) (Fig. 2f). The final two high-prevalence peptides belonged to the trans-sialidase family (Fig. 3a) and shared the sequence APGETK[V/I]PSELNATIPSDHDILLEFR[D/E]LAAMALIG. To our knowledge, this peptide is novel as a diagnostic antigen candidate.

## Epitope mapping and validation of the high-prevalence trans-sialidase antigen

To orthogonally validate antibody reactivity to the high-prevalence trans-sialidase peptide, we performed a split-luciferase binding assay (SLBA). Briefly, we generated the trans-sialidase

peptide with a C-terminal HiBiT tag and immunoprecipitated it with plasma from 4 seropositive BD patient samples with the highest PhIP-seq RPK values and five independent healthy US controls. Incubation of the immunoprecipitated peptides with LgBiT produces luminescence as a quantitative measurement of antibody binding. Four Chagas disease seropositive samples with high PhIP-seq enrichment were reactive to the trans-sialidase peptide, while seronegative control samples were not (Fig. 3b).

A sequential alanine-scan was performed to further map the reactive epitope of the trans-sialidase peptide. Using samples from 5 seropositive BD patients, we determined that the critical region for immunoreactivity was a ten aa sequence that spans positions 648 to 658 of the full-length trans-sialidase protein (DILLEFRELA) (Fig. 3c). To be permissive of the epitope we chose a final antigenic sequence of IPSDHDILLEFRELA, corresponding to the two alanine blocks with the lowest reactivity, henceforth be referred to as TS-2.23. Basic local alignment search tool (BLAST) analysis of TS-2.23 in NCBI database identified 37 proteins from all *T. cruzi* entries with >93% (15-aa) sequence identity, all of which were from trans-sialidase or putative trans-sialidase genes.




**Fig. 3. A novel trans-sialidase peptide sequence is a highly reactive serological antigen.** (**A**) Anti-trans-sialidase peptide antibody reactivity is plotted as RPK. The dotted red line signifies the RPK that corresponds to a z-score cutoff of 5 in the seronegative population of each cohort. (**B**) Trans-sialidase reactivity orthogonal validation using a split-luciferase binding assay (SLBA). Reactivity was tested against four seropositive blood donor specimens and five seronegative US healthy control specimens. (**C**) Alanine-scanning mutagenesis in 10-aa windows (highlighted in red) across the entire trans-sialidase antigenic fragment demonstrates the seroreactive epitope in Chagas disease.

261 Values are normalized antibody indices and represent the averages of five seropositive
262 blood donor specimens.

263 **Evaluation of trans-sialidase antigen TS-2.23 antibody reactivity**

264 To evaluate the potential of TS-2.23 as a diagnostic serology antigen, we compared its PhIP-seq
265 performance to that of current diagnostic antigens. To address the fact that current diagnostic
266 antigen sequences vary at certain amino acids from available sequencing data (*33*) and the
267 specific antigen sequences used in commercial diagnostics are not publicly available for all
268 assay, we agnostically derived the aa sequence motifs of eight diagnostic antigens used in US
269 Food and Drug Administration (FDA)-cleared serology tests (*24*) using Multiple EM for Motif
270 Elicitation (MEME) (see *Materials and Methods*) (Fig. S6) (*34-36*). These motifs were then
271 queried against the entire *T. cruzi* PhIP-seq proteome using FIMO to identify all peptides with a
272 significantly similar sequence to each antigen (*37*). The maximum z-score for each BD sample
273 across all PhIP-seq peptides with a sequence match to a given antigen motif was plotted (Fig.
274 4a). The maximum z-score across all peptides with a sequence match to TS-2.23 was also shown
275 to compare the novel antigen reactivity to those in used in current diagnostics. Any sample with
276 a z-score of at least 5 for a peptide that contained an antigen motif was considered enriched for
277 antibody reactivity prevalence calculations (Fig. 4b). TS-2.23 had high prevalence, demonstrated
278 in 100% (64/64) of the seropositive BD samples and 95% (108/114) of CBM seropositive
279 samples. By comparison, only Ag 2 and TcE had similar antibody reactivity and prevalence
280 across seropositive specimens. In contrast, Ag 1, Ag13 and Ag36 had similar prevalence but
281 lower reactivity, and KMP-11 was rarely enriched.
282




B

| Antigen | BD Prevalence (*n* = 64) | CBM Prevalence (*n* = 114) |
|---|---|---|
| Ag2 | 98% | 97% |
| TcE | 98% | 95% |
| Ag1 | 95% | 98% |
| SAPA | 95% | 93% |
| Ag13 | 94% | 82% |
| Ag36 | 89% | 96% |
| Ag30 | 47% | 77% |
| KMP-11 | 6% | 12% |
| TS-2.23 | 100% | 95% |

283
284 **Fig. 4. PhIP-seq antibody reactivity of current diagnostic antigens and TS-2.23 within**
285 **individual Chagas disease seropositive specimens.** Recombinant antigens in current
286 FDA-cleared serology tests include Ag 1, Ag 2, Ag 13, Ag 30, Ag 36 (33, 34), shed acute
287 phase antigen (SAPA) (35), KMP-11 (36), TcD and TcE (30, 37). Note, TcD contains the
288 same antigenic epitope as Ag 13. (**A**) Heatmap of z-score enrichment over seronegative
289 controls in the seropositive blood donor (BD) specimens (n=64). Each antigen motif was
290 derived using Multiple EM for Motif Elicitation (MEME) and then scored against the
291 entire *T. cruzi* PhIP-seq proteome. The maximum z-score across all peptides with
292 significant sequence matches to a given antigen motif was plotted for each sample and
293 each antigen. (**B**) Percent of samples enriched ( z-score ≥5) for each antigen in BD and
294 cardiac biomarker (CBM) specimen sets.

To further validate and directly characterize the antibody reactivity of TS-2.23, we performed a quantitative IgG biolayer interferometry (BLI) immunoassay on 336 BD specimens with previous Chagas disease serology testing (n=250, seropositive; n=86, seronegative) (*Materials and Methods*, Fig. 5a). Seropositive samples were chosen to include all specimens with region of origin data (Mexico, n=92; Central America, n=86; South America, n=72) (Fig. 5b). The results of the pairwise comparisons between regions demonstrated seroreactivity was lower in individuals from Mexico compared to Central America ($p<0.0001$) and South America ($p=0.00021$). Specimens from individuals from Central America and South America did not show differences in reactivity ($p=1.000$). Seronegative specimens did not demonstrate any overt non-specific reactivity to the TS-2.23 antigen.




**Fig. 5. Biolayer interferometry validates trans-sialidase antigen TS-2.23 seroreactivity in a large cohort.** (**A**) Schematic of biolayer interferometry (BLI) approach. BLI uses a fiberoptic probe to measure the wavelength of light reflected from the surface of a biosensor, which changes due to light interference when an analyte binds. First, an anti-His tag probe is incubated with His-tagged antigen. Then, the probe is incubated in diluted serum or plasma, and antibodies bind the immobilized antigen on the probe. To quantify IgG-specific reactivity, anti-IgG antibodies are added and bind the immobilized patient antibodies. (**B**) Seropositive blood donor specimens (n = 250) demonstrate a range of reactivity to the trans-sialidase antigen by quantitative BLI immunoassay, while seronegative blood donor specimens (n=86) do not (Wilcoxon rank-sum test). Reactivity, as denoted by wavelength shift, was higher in Central American (n=86) and South American (n=72) specimens than in Mexican specimens (n=92). Dashed line corresponds to the 25th percentile across all seropositive specimens.

To evaluate if specimens with low reactivity to TS-2.23 are weakly reactive overall, we compared TS-2.23 reactivity with previous results from an FDA-cleared Chagas disease serology ELISA (Chagatest Recombinante v.3.0, Wiener Labs [Wv3]). This assay contains a multi-epitope recombinant antigen comprised of Ag 1, Ag 2, Ag 13, Ag 30, Ag 36, and SAPA (*30, 31*). Analysis of the 25$^{th}$ percentile of TS-2.23 BLI reactivity yielded 63 specimens originally positive

325 by blood donor testing. The reactivity (signal-to-cutoff ratio) of the Wv3 ELISA was in the 25th
326 percentile of previous testing (*12*) for 70% (44/63) of the low reactive TS-2.23 BLI specimens.
327 This comparison to previous Wv3 ELISA test results suggests that most low reactivity TS-2.23
328 specimens are weakly reactive specimens overall. Breakdown of these specimens by region of
329 origin included 60% (38/63) from Mexico, 24% (15/63) from Central America, and 16% (10/63)
330 from South America.

331 **DISCUSSION**

332 Chagas disease is a neglected tropical disease endemic to the Americas, affecting over 6 million
333 people worldwide (*1*). Numerous diagnostic challenges for chronic Chagas disease exist,
334 including low clinical awareness, non-specific or asymptomatic presentation, and imperfect test
335 performance (*38, 39*). In addition to better testing for populations with epidemiological risk
336 factors for exposure to triatomine vectors, effective testing is needed for at-risk people presenting
337 for prenatal screening, blood donation and organ transplant evaluation (*8-11*). The major
338 disparities for Chagas disease serology testing are insufficient sensitivity and specificity of any
339 one diagnostic test to be used alone and differential serological test performance by region of
340 origin of *T. cruzi* infection.

341 To address this, we carried out our *T. cruzi* PhIP-seq study in two well-characterized Chagas
342 disease specimen sets, which represent the largest number of samples evaluated for *T. cruzi*
343 antigen discovery, to our knowledge. One set (BD) includes specimens from individuals born in
344 Mexico, Central America and South America, collected via blood donation in the US (*12*). An
345 additional set (CBM) includes Bolivians with varying stages of Chagas cardiomyopathy,
346 collected via a clinical study of cardiac biomarkers (*40*). Analysis of these two specimen sets by
347 PhIP-seq identified more than 1,300 reactive *T. cruzi* peptides highly specific to individuals with
348 Chagas disease. Down selection on common antigens amongst Chagas disease seropositive
349 individuals filtered to only three antigenic sequences with sufficient prevalence for diagnostic
350 utility (enrichment in ≥90% of specimens). This vast difference between total reactive peptides
351 and high-prevalence antigens illustrates the uniqueness of the adaptive immune system response
352 within an individual host. By contrast, the rare high-prevalence antigens warrant further research
353 into the host-pathogen biology that drives their immunodominance.

354 Two of these high-prevalence antigens were identified by multiple groups from early phage
355 display studies and are already incorporated into current serological diagnostics: Ag 2 (*30, 31*), a
356 nucleoporin protein, and TcE (*41*), a 60S ribosomal subunit protein. The third and, in fact, most
357 prevalent peptide antigen discovered in our study, TS-2.23, has not previously been described as
358 a serological diagnostic antigen and belongs to the trans-sialidase family. Trans-sialidase
359 enzymes comprise a unique pathogenic and antigenic family of secreted and
360 glycophosphatidylinositol (GPI)-anchored cell surface proteins in *T. cruzi*. Their primary
361 functional activity is to transfer sialic acids from mammalian cells to beta-galactosidase residues
362 on *T. cruzi's* cell membrane to assist in cell invasion (*42*). Trans-sialidases also appear to
363 modulate the host immune response, likely acting as decoy antigens (*43*). The evidence for this
364 relates to the discovery of the shed acute phase antigen (SAPA), a multi-repeat antigen located at
365 the C-terminal end of trans-sialidase enzymes (*44*). Since the catalytic end is in the N-terminal
366 region, it is hypothesized that C-terminal antigens evolved to protect the trans-sialidase enzyme
367 activity from humoral responses. BLAST analysis of the trans-sialidase antigen identified by our
368 study showed 37 *T. cruzi* proteins with >93% sequence identity, all of which were trans-sialidase

369 or putative trans-sialidase genes. All sequences were located at C-terminal end, matching with
370 the immunodominant nature of known antigens from this family.

371 Our findings also demonstrate that the TS-2.23 antigen identified in this study has increased
372 antibody reactivity in specimens from individuals born in Central America, compared to
373 previous analyses of the same specimens by current clinical diagnostics (*12*). Beyond the
374 potential implications for endemic populations in Central America, identification of TS-2.23 is
375 important for screening and diagnosis in the US considering that a large proportion of the Latin
376 American immigrant population is predominantly from El Salvador and Guatemala. Further
377 studies evaluating Central American Chagas disease populations with a combination of
378 conventional antigens and TS-2.23 will be needed to identify real-world increases in diagnostic
379 test performance. While this is a promising advancement, unfortunately, TS-2.23 does not have
380 improved seroreactivity in individuals who acquired *T. cruzi* infection in Mexico. Further study
381 is needed to evaluate whether this is due to lower anti-*T. cruzi* IgG levels in individuals exposed
382 in Mexico or the absence of regional *T. cruzi* antigens of Mexican origin. Post-translational
383 protein glycosylation may be a source of unique antigenicity outside of the primary peptide
384 sequence (*45*).

385 Our study is limited by retrospective selection bias on samples tested by current diagnostic
386 assays. Prospective testing in at-risk populations will be important to further validate the TS-2.23
387 antigen. We do not report on the sensitivity or specificity of the TS-2.23 antigen in comparison
388 to previous testing because these assays contain between 6 to 9 different antigens in a
389 multiepitope format. The evaluation of test performance by TS-2.23 should be done in
390 combination with these recombinant multiepitope assays to generate test performance
391 characteristics, which are planned for follow-on studies. Ultimately, to create the ideal serologic
392 test for diagnosis of chronic Chagas disease, we would combine the fewest recombinant targets
393 for a multiepitope antigen that approaches 100% sensitivity and specificity to eliminate the need
394 for confirmatory testing for all initial *T. cruzi* seropositive results. Such a test would greatly
395 facilitate Chagas disease screening, diagnosis, and treatment.

396 In summary, our study has discovered a novel *T. cruzi* trans-sialidase peptide antigen (TS-2.23)
397 that is serologically reactive and prevalent across endemic countries of Latin America and
398 varying degrees of cardiac disease severity. Future studies will evaluate the real-world test
399 performance in traditional immunoassay formats common in clinical laboratories.

## 400 MATERIALS AND METHODS

### 401 Study Design

402 Samples used in this study included blood donor plasma collected within the US and serum from
403 clinical research collected in Bolivia. The blood donor plasma samples were provided in
404 collaboration with the American Red Cross (ARC) with sample selection criteria described
405 previously (*12*). All blood donor specimens (BD) were confirmed by blood donor testing assays
406 and algorithms (*9*). A subset of specimens was used for antigen discovery experiments (n=90;
407 n=64, seropositive; n=26, seronegative). Region of origin data was available for 35 specimens
408 (n=13, Mexico; n=10, Central America; n=12, South America). The serum samples from clinical
409 research studies in Bolivia were collected as part of a cardiac biomarker (CBM) study (*40*).
410 Specimens were collected from a large public hospital in Santa Cruz, tested and confirmed for *T.*
411 *cruzi* serostatus and further stratified for cardiac status by clinical assessment, electrocardiogram
412 and echocardiography studies. In total, 143 serum samples were included for this study,

413 including 22 seronegative (n=15, without significant cardiac abnormalities [Stage A]; n=7, with
414 cardiac abnormalities [Stage B]) and 121 seropositive (n=40, without significant cardiac
415 abnormalities [Stage A]; n= 81, with cardiac abnormalities[Stages B-D]). Cardiac staging is
416 defined as: A, normal electrocardiogram (ECG), normal echocardiography (echo); B, abnormal
417 ECG, normal echo; C, 40-55% ejection fraction (EF) by echo, normal left ventricular end
418 diastolic diameter (LVEDD); D, EF<40% or LVEDD >57mm. Specimens were randomized to
419 96-well plates prior to testing and frozen at -20˚C. A separate set of *T. cruzi* seronegative plasma
420 specimens (n=95) from the New York Blood Center (NYBC) was used as an independent
421 negative control for antigen discovery experiments with the CBM specimen set.

422 Institutional review board for research use of de-identified human biospecimens was approved
423 by the University of California San Francisco. The BD study protocol was approved by
424 institutional review board at the American Red Cross. The CBM study protocol was approved by
425 the Institutional Review Boards of Universidad Catolica Boliviana (Santa Cruz, Bolivia) and
426 included consent for future use of deidentified specimens (*40*). NYBC specimens consisted of
427 de-identified plasma obtained from adults who donated blood to the New York Blood Center.

428 **Construction of *T. cruzi* phage library**

429 Reference protein sequences for the *T. cruzi* strain CL Brener assembly GCF_000209065.1 (*46*)
430 were obtained from the National Center of Biotechnology Information (NCBI) site. All
431 sequences in the peptidome were processed using a previously described bioinformatic pipeline
432 (*47*). Briefly, all full-length protein sequences were decomposed into a series of overlapping
433 peptides. Each peptide was 47 amino acids in length with consecutive peptides overlapping by
434 19 amino acids. The full set of peptides was collapsed using the command line tool cd-hit (*48,*
435 *49*) at 90% sequence similarity, resulting in a final set of 228,127 peptides spanning the *T. cruzi*
436 peptidome (19,607 proteins). Peptides tiling over the length of the glial fibrillary acidic protein
437 (GFAP) were added to the library as a positive control for immunoprecipitation. Peptide
438 sequences were converted to their coding DNA sequences with common 5'
439 (GTAGCTGGTGTTGTAGCTGCC) and 3' (GGTGACTACAAGGATGATGATGATAAA)
440 linker sequences appended to each peptide encoding sequence. The 3' linker sequence encoded a
441 FLAG tag). The final library, consisting of 228,162 peptides that correspond to 19,608 proteins,
442 was ordered from Agilent Technologies.

443 **Cloning and packaging into T7 phage**

444 The oligo pool was received in a single tube, lyophilized, and was resuspended to 0.2 nM. The
445 pool was amplified using Phusion polymerase (New England Biolabs [NEB]) and linker-specific
446 primers (TAGTTAAGCGGAATTCAGTAGCTGGTGTTGTAGCTGCC,
447 ATCCTGAGCTAAGCTTTTTATCATCATCATCCTTGTAGTCACC). The amplified library
448 was purified using Ampure XP magnetic beads (Beckman Coulter) and confirmed to have a
449 single-size product by gel electrophoresis. One µg of the cleaned library was then digested using
450 EcoRI-HF and HindIII-HF restriction enzymes (NEB) and purified again using Ampure XP
451 beads. Digestion of the library product was confirmed by visualizing a 20bp size shift using the
452 Bioanalyzer High Sensitivity DNA Analysis kit (Agilent). The digested library was cloned into
453 T7 Select vector arms (Novagen 70550-3) as previously described (*47*). Four packaging
454 reactions were performed and then pooled. The final phage library was grown up in BLT5403 *E.*
455 *coli* (Novagen 70550-3).

456 **Immunoprecipitation of antibody-bound phage**

457 PhIP-seq was performed using the *T. cruzi* peptide phage display library with plasma or serum
458 samples using our previously-published PhIP-seq protocol (https://www.protocols.io/view/derisi-
459 lab-phage-immunoprecipitation-sequencing-ph-4r3l229qxl1y/v1). Patient plasma was diluted 1:1
460 in storage buffer (0.04% NaN3, 40% Glycerol, 40 mM HEPES (pH 7.3), 1 x PBS (-Ca and –
461 Mg)) to preserve antibody integrity. One uL of diluted plasma was incubated with 500 µL of the
462 input phage display library for the first round of immunoprecipitation. Positive control
463 immunoprecipitations were performed using 1 µL of 1:10 diluted anti-GFAP antibody (Dako,
464 Z0334) (Figure S2). Ten µL of Dynabeads Protein A/G slurry (ThermoFisher Scientific) were
465 used per sample. After one round of immunoprecipitation, phage were amplified in *E. coli* and
466 enriched in a second round of immunoprecipitation. The final lysate was spun and stored at 4 °C
467 for NGS library prep. Immunoprecipitated phage lysate was heated to 70 °C for 15 min to expose
468 DNA. DNA was then prepared for next-generation sequencing in two subsequent PCR
469 amplifications. The final prepared libraries were sequenced using an Illumina sequencer to a read
470 depth of approximately 1 million reads per sample.

471 **PhIP-seq data analysis**

472 Sequencing reads from fastq files were aligned to the reference *T. cruzi* peptide library and
473 individual peptide counts were normalized to reads per 100,000 (RPK) by dividing by the sum of
474 counts and multiplying by 100,000 to account for varying read depth. All subsequent analyses
475 were performed using Python (version 3.12.2) unless otherwise noted.

476 To identify Chagas disease-specific enriched peptides and avoid false positives, a conservative
477 analysis pipeline was used as follows. Peptide-level enrichment across known seronegative
478 samples was calculated and used to generate z-scores ((x-mean seronegative)/standard deviation
479 seronegative) for the Chagas disease seropositive, seronegative, and NYBC control samples. The
480 z-score for any seronegative sample was calculated by leaving out that sample from the mean of
481 seronegative samples for each peptide. A moving threshold analysis was implemented to
482 determine the z-score threshold and the number of Chagas disease patients that must share
483 enrichment to a given peptide to completely differentiate seropositive and seronegative patients
484 (Figure S3). Based on this analysis, z-score cutoff of 5 and shared enrichment across at least five
485 percent of Chagas disease samples (n≥3 BD specimens; n≥ 5 CBM specimens) and one or fewer
486 seronegative samples was set for hit calling.

487 Additional validation of the z-score approach was executed using a mass univariate analysis
488 using generalized linear models applied to each peptide. Peptide fragments with uniform values
489 across all samples were removed due to lack of variability. RPK values were scaled by
490 subtracting the mean and dividing by the standard deviation calculated within each peptide.
491 Scaled RPK values for each peptide were regressed on Chagas disease diagnostic status ($y_i = \beta_{0i}$
492 $+ \beta_{1i} \cdot x$) where $y_i$ is the scaled RPK value, $\beta_{0i}$ is the intercept of the $i$-th peptide fragment, $\beta_{1i}$ is
493 the predictor coefficient, and $x$ is the diagnostic status in BD samples or cardiac disease stage in
494 CBM samples. The resulting coefficient quantified the strength and direction of the association
495 between diagnostic status (or disease stage) and the scaled RPK values for each peptide, where
496 positive coefficient values represent, on average, a higher RPK for that peptide in seropositive
497 specimens. Analyses were performed using R (version 4.3.1).

498 Antigenic prevalence of a *T. cruzi* peptide was calculated as the number of seropositive samples
499 enriched for a specific peptide divided by the number of seropositive samples in the respective

500 specimen set (BD and CBM). High-prevalence antigens were designated as enrichment in ≥90%
501 of seropositive specimens and no seronegative specimens.

502 **Split Luciferase Binding Assay (SLBA)**

503 A high-prevalence antigen by PhIP-seq that was not already included in commercial diagnostics
504 was selected for orthogonal validation by SLBA. A detailed SLBA protocol can be found online
505 at https://www.protocols.io/view/split-luciferase-binding-assay-slba-protocol-4r3l27b9pg1y/v1.
506 Briefly, the high-prevalence peptide antigen was inserted into a split luciferase construct
507 containing a T7 promoter and a terminal HiBiT tag and synthesized as DNA oligomers (Twist
508 Biosciences). The oligos were amplified using 5′-
509 AAGCAGAGCTCGTTTAGTGAACCGTCAGA-3′ and 5′-
510 GGCCGGCCGTTTAAACGCTGATCTT-3′ primer pair and purified using the DNA Clean and
511 Concentrator-5 kit (Zymo). Purified PCR products were transcribed and translated *in vitro*
512 (IVTT) using wheat germ extract (Promega L4140) and the Nano-Glo HiBiT Lytic Detection
513 System (Promega, N3040) was used to quantify translated protein using relative luciferase units
514 (RLU) detected on a luminometer. Background luminescence was calculated using an IVTT
515 reaction that used a construct encoding a STOP codon 5' of the HiBiT tag. Peptides were
516 normalized to 2 x $10^7$ RLU per well, incubated overnight with patient plasma or a positive
517 control anti-HiBiT antibody (Promega, N7200), and immunoprecipitated with a Dynabeads
518 Protein A/G bead slurry. The immunoprecipitation was washed four times with SLBA buffer
519 (0.15 M NaCl, 0.02 M Tris-HCl pH 7.4, 1% w/v sodium azide, 1% w/v bovine serum albumin,
520 and 0.15% v/v Tween 20) and remaining luminescence was measured using the Nano-Glo HiBiT
521 Lytic Detection System in a luminometer. Antibody index was calculated as (RLU sample –
522 RLU mock IP)/(RLU sample – RLU anti-HiBiT) for orthogonal validation of the trans-sialidase
523 peptides. For epitope mapping by alanine-scanning mutagenesis, the antibody index was
524 calculated as (RLU seropositive – RLU US control)/(RLU seropositive – RLU anti-HiBiT) and
525 normalized to the antibody index of immunoprecipitation using the wild-type peptide sequence.

526 **MEME and FIMO Motif Analysis**

527 To empirically re-derive a selected diagnostic antigen motif, all BD-enriched peptides were
528 filtered to those peptides that mapped to the antigenic protein (e.g., any enriched peptide that
529 belonged to a nucleoporin protein for Ag2). These peptide sequences were queried using *MEME*
530 (MEME 5.5.7) with the following *meme* command options and parameters:

531 -protein -mod zoops -nmotifs 10 -minw 6 -maxw 15 -objfun classic -markov_order 0

532 The derived motifs were then manually inspected to identify the motif that clearly matched the
533 published diagnostic antigen sequences (Figure S6) (*24*). This motif (or multiple motifs, if the
534 antigen sequence was over 47 amino acids, as in the case of Ag1 and Ag36) was then queried
535 against the entire *T. cruzi* PhIP-seq proteome using the following *fimo* command options and
536 parameters:

537 --thresh 1e-4 --qv-thresh

538 The only exceptions to this analysis were antigens Ag13, TcE, and KMP-11. Ag13 and TcE are
539 short, highly repetitive antigens, and so were identified using the *meme* parameter -mod anr. The
540 final antigenic motif identified for TcE was very short (6 amino acids) and thus required
541 different *fimo* significance thresholds to identify similar sequences. A q-value threshold of 1e-2
542 was set for this antigen only. Finally, KMP-11 was represented by only three overlapping

543 peptides that map to kinetoplastid membrane protein KMP-11 (XP_808865.1), so motif
544 discovery was not possible. To look for sequence similarity across the *T. cruzi* proteome, the 92-
545 amino acid KMP-11 protein was queried against the proteome using *blastp* (BLAST 2.12.0) and
546 no other peptides with significant sequence similarity were identified. The three KMP-11
547 peptides alone were used for downstream analysis of KMP-11 antigen reactivity.

548 To assess the reactivity of patient samples against these antigen motifs, the maximum z-score
549 across all peptides with a sequence match to a given antigen motif was plotted for each BD
550 sample.

551 **Peptide Antigen Expression**

552 We selected a minimal antigenic peptide sequence that consisted of the 15-aa that, when mutated
553 via alanine scanning, produced the lowest binding signal on SLBA (Figure 3c), to test using
554 biolayer interferometry (BLI). This peptide sequence was repeated seven times in series to create
555 a final protein that was approximately 13 kDa. The insert sequence was synthesized by Twist
556 Bioscience in a pET-21(+) vector, with a C-terminal 6X His tag and under control of a T7
557 promoter and lac repressor.

558 The expression plasmid was transformed into BL21(DE3) competent *E. coli* (Thermo
559 Scientific) and plated onto Luria-Bertani (LB) agar plates containing carbenicillin. Isolates were
560 expanded in 1L LB broth with carbenicillin grown at 37°C to an OD600 of 0.6. The culture was
561 induced with 1mM Isopropyl β-D-1-thiogalactopyranoside and grown at 25°C shaking for
562 another 18 hours. The cells were then centrifuged at 10,000 RPM for 30 minutes at 4°C to collect
563 the cell pellet.

564 A stock lysis buffer (20 mM sodium phosphate, 20 mM imidazole, 500 mM NaCl, 0.5 mM
565 TCEP, 5% glycerol, pH 7.4) was made with EDTA-free (Roche) per 50 mL. The pelleted cells
566 were resuspended in 100mL of cold lysis buffer and run through a LM10 microfluidizer at
567 15,000 PSI for 5 cycles. The flowthrough lysate was collected after each cycle and combined.
568 The lysate was centrifuged at 12,500 RPM for 30 minutes at 4°C. The supernatant was collected
569 and filtered through a 0.22 µm vacuum filtration device.

570 Recombinant His-tagged antigen was purified from the filtered lysate using a Ni-NTA resin
571 gravity flow column. After loading the lysate to the column, the column was washed with a wash
572 buffer (20 mM sodium phosphate, 40 mM imidazole, 500 mM NaCl, 0.5 mM TCEP, pH 7.4).
573 The antigen was eluted with an elution buffer (20 mM sodium phosphate, 500 mM imidazole,
574 500 mM NaCl, 0.5 mM TCEP, pH 7.4). Peptide yield from the purification was quantified using
575 NanoDrop (Thermo Scientific), and the purity of the product was verified by protein gel
576 electrophoresis. Expression of the peptide was confirmed by anti-His tag Western blot using a
577 6X-His tag monoclonal antibody (Invitrogen, MA1-21315).

578 **Biolayer Interferometry (BLI) Serological Immunoassay**

579 A GatorPrime analyzer (Gator Bio) was used to perform BLI to evaluate the antibody reactivity
580 to the recombinant peptide antigen. BLI uses a fiberoptic probe to measure the wavelength of
581 light (nanometers [nm]) reflected from the surface of a biosensor, which shifts in response to
582 analyte binding (Figure 5a). Quantitative BLI serological immunoassay can be performed by
583 measuring nm shift to antigen-bound probe incubated in diluted serum or plasma and
584 subsequently in anti-human immunoglobulin (IgG) for quantifying class-specific responses. BLI
585 methodology was chosen for these analyses because it has a higher dynamic range for assessing

antibody-antigen reactivity compared to traditional colorimetric enzyme-linked immunosorbent assays (ELISA) (*50*). An anti-*T. cruzi* IgG BLI method was developed using a commercial *T. cruzi* Chimeric Chagas Multi-Antigen (MACH; Jena Biosciences). This is a polypeptide chain of 87-aas with epitopes from previously known antigens: Peptide 2, TcD, TcE, and SAPA, fused with a 6His-Tag. This BLI method was optimized using high, intermediate, and low reactivity seropositive BD specimens previously determined by Chagatest Recombinante v.3.0 anti-T.cruzi ELISA (Wiener Labs), which contain the MACH antigens.

The anti-*T.cruzi* IgG BLI assay was adapted for the recombinant antigen discovered by PhIP-seq by varying the protein concentration to achieve saturation of nm shift signal of the anti-His tag fiberoptic probe (Figure S7). The final method consisted of the following BLI conditions: 1) 600 second (s) incubation of anti-His probe in 2ug/mL peptide antigen, 2) 1800s incubation in 10uL of plasma diluted 1:19 with Q-Buffer diluent (GatorBio), and 3) 2000s incubation in a solution of 10ug/mL goat anti-human IgG (Jackson Immunoresearch). Steps 1 and 2 were followed by a 360s wash in Q-Buffer. Endpoint nm shift measurements were normalized by subtracting the nm shift value after antigen loading wash (step 1) to account for any minor variation in the amount of immobilized antigen.

Anti-*T. cruzi* IgG BLI was performed on 336 BD specimens (n = 250, seropositive; n=86, seronegative) to evaluate antibody reactivity to the peptide antigen. Region of origin data was available for all seropositive specimens (Mexico, n=92; Central America, n=86; South America, n=72). Wilcoxon rank sum analysis with a correction for multiple comparisons using the Bonferroni method was completed to compare reactivity between regions.

**Statistical analysis**

Associations between number of individual antibody targets and heart disease stage or region of infection were tested using Kruskal-Wallis tests. Motif analysis was performed using MEME and FIMO (*34-36*). Associations between anti-TS-2.23 BLI reactivity, serologic status, and region were tested using the Wilcoxon rank-sum test with a correction for multiple comparisons using the Bonferroni method.

**List of Supplementary Materials**

Fig. S1 to S7

Table S1

**References and Notes**

1. S. World Health Organization = Organisation mondiale de la, Chagas disease in Latin America : an epidemiological update based on 2010 estimates = Maladie de Chagas en Amérique latine : le point épidémiologique basé sur les estimations de 2010. *Weekly Epidemiological Record = Relevé épidémiologique hebdomadaire* **90**, 33-44 (2015).
2. A. Irish, J. D. Whitman, E. H. Clark, R. Marcus, C. Bern, Updated Estimates and Mapping for Prevalence of Chagas Disease among Adults, United States. *Emerg Infect Dis* **28**, 1313-1320 (2022).
3. C. Bern, L. A. Messenger, J. D. Whitman, J. H. Maguire, Chagas Disease in the United States: a Public Health Approach. *Clin Microbiol Rev* **33**, (2019).

4. M. C. P. Nunes, A. Beaton, H. Acquatella, C. Bern, A. F. Bolger, L. E. Echeverria, W. O. Dutra, J. Gascon, C. A. Morillo, J. Oliveira-Filho, A. L. P. Ribeiro, J. A. Marin-Neto, E. American Heart Association Rheumatic Fever, Y. Kawasaki Disease Committee of the Council on Cardiovascular Disease in the, C. Council on, N. Stroke, C. Stroke, Chagas Cardiomyopathy: An Update of Current Clinical Knowledge and Management: A Scientific Statement From the American Heart Association. *Circulation* **138**, e169-e209 (2018).
5. A. Perez-Ayala, J. A. Perez-Molina, F. Norman, B. Monge-Maillo, M. V. Faro, R. Lopez-Velez, Gastro-intestinal Chagas disease in migrants to Spain: prevalence and methods for early diagnosis. *Ann Trop Med Parasitol* **105**, 25-29 (2011).
6. R. B. de Oliveira, L. E. Troncon, R. O. Dantas, U. G. Menghelli, Gastrointestinal manifestations of Chagas' disease. *Am J Gastroenterol* **93**, 884-889 (1998).
7. Pan American Health Organization. (2019), vol. 2021.
8. C. J. Forsyth, J. Manne-Goehler, C. Bern, J. Whitman, N. S. Hochberg, M. Edwards, R. Marcus, N. L. Beatty, Y. E. Castro-Sesquen, C. Coyle, P. Stigler Granados, D. Hamer, J. H. Maguire, R. H. Gilman, S. Meymandi, Recommendations for Screening and Diagnosis of Chagas Disease in the United States. *J Infect Dis* **225**, 1601-1610 (2022).
9. R. Y. Dodd, J. A. Groves, R. L. Townsend, E. P. Notari, G. A. Foster, B. Custer, M. P. Busch, S. L. Stramer, Impact of one-time testing for Trypanosoma cruzi antibodies among blood donors in the United States. *Transfusion* **59**, 1016-1023 (2019).
10. O. P. T. N. . (2023), vol. 2023.
11. P. V. Chin-Hong, B. S. Schwartz, C. Bern, S. P. Montgomery, S. Kontak, B. Kubak, M. I. Morris, M. Nowicki, C. Wright, M. G. Ison, Screening and treatment of chagas disease in organ transplant recipients in the United States: recommendations from the chagas in transplant working group. *Am J Transplant* **11**, 672-680 (2011).
12. J. D. Whitman, C. A. Bulman, E. L. Gunderson, A. M. Irish, R. L. Townsend, S. L. Stramer, J. A. Sakanari, C. Bern, Chagas Disease Serological Test Performance in U.S. Blood Donor Specimens. *J Clin Microbiol* **57**, (2019).
13. Y. E. Castro-Sesquen, A. Saldana, D. Patino Nava, T. Bayangos, D. Paulette Evans, K. DeToy, A. Trevino, R. Marcus, C. Bern, R. H. Gilman, K. R. Talaat, P. Chagas Working Group in, S. the United, Use of a Latent Class Analysis in the Diagnosis of Chronic Chagas Disease in the Washington Metropolitan Area. *Clin Infect Dis* **72**, e303-e310 (2021).
14. C. Truyens, E. Dumonteil, J. Alger, M. L. Cafferata, A. Ciganda, L. Gibbons, C. Herrera, S. Sosa-Estani, P. Buekens, Geographic Variations in Test Reactivity for the Serological Diagnosis of Trypanosoma cruzi Infection. *J Clin Microbiol* **59**, e0106221 (2021).
15. E. A. Kelly, C. A. Bulman, E. L. Gunderson, A. M. Irish, R. L. Townsend, J. A. Sakanari, S. L. Stramer, C. Bern, J. D. Whitman, Comparative Performance of Latest-Generation and FDA-Cleared Serology Tests for the Diagnosis of Chagas Disease. *J Clin Microbiol*, (2021).
16. J. R. Verani, A. Seitz, R. H. Gilman, C. LaFuente, G. Galdos-Cardenas, V. Kawai, E. de LaFuente, L. Ferrufino, N. M. Bowman, V. Pinedo-Cancino, M. Z. Levy, F. Steurer, C. W. Todd, L. V. Kirchhoff, L. Cabrera, M. Verastegui, C. Bern, Geographic variation in the sensitivity of recombinant antigen-based rapid tests for chronic Trypanosoma cruzi infection. *Am J Trop Med Hyg* **80**, 410-415 (2009).

673 17. D. Guzman-Gomez, A. Lopez-Monteon, M. de la Soledad Lagunes-Castro, C. Alvarez-
674 Martinez, M. J. Hernandez-Lutzon, E. Dumonteil, A. Ramos-Ligonio, Highly discordant
675 serology against Trypanosoma cruzi in central Veracruz, Mexico: role of the antigen used
676 for diagnostic. *Parasit Vectors* **8**, 466 (2015).
677 18. E. Z. Caballero, R. Correa, M. S. Nascimento, A. Villarreal, A. Llanes, N. Kesper, Jr.,
678 High sensitivity and reproducibility of in-house ELISAs using different genotypes of
679 Trypanosoma cruzi. *Parasite Immunol* **41**, e12627 (2019).
680 19. R. Gamboa-Leon, C. Gonzalez-Ramirez, N. Padilla-Raygoza, S. Sosa-Estani, A. Caamal-
681 Kantun, P. Buekens, E. Dumonteil, Do commercial serologic tests for Trypanosoma cruzi
682 infection detect Mexican strains in women and newborns? *J Parasitol* **97**, 338-343
683 (2011).
684 20. B. Zingales, M. A. Miles, D. A. Campbell, M. Tibayrenc, A. M. Macedo, M. M. Teixeira,
685 A. G. Schijman, M. S. Llewellyn, E. Lages-Silva, C. R. Machado, S. G. Andrade, N. R.
686 Sturm, The revised Trypanosoma cruzi subspecific nomenclature: rationale,
687 epidemiological relevance and research applications. *Infect Genet Evol* **12**, 240-253
688 (2012).
689 21. A. Marcili, L. Lima, M. Cavazzana, A. C. Junqueira, H. H. Veludo, F. Maia Da Silva, M.
690 Campaner, F. Paiva, V. L. Nunes, M. M. Teixeira, A new genotype of Trypanosoma
691 cruzi associated with bats evidenced by phylogenetic analyses using SSU rDNA,
692 cytochrome b and Histone H2B genes and genotyping based on ITS1 rDNA.
693 *Parasitology* **136**, 641-655 (2009).
694 22. K. A. Alroy, C. Huang, R. H. Gilman, V. R. Quispe-Machaca, M. A. Marks, J. Ancca-
695 Juarez, M. Hillyard, M. Verastegui, G. Sanchez, L. Cabrera, E. Vidal, E. M. Billig, V. A.
696 Cama, C. Naquira, C. Bern, M. Z. Levy, P. Working Group on Chagas Disease in,
697 Prevalence and Transmission of Trypanosoma cruzi in People of Rural Communities of
698 the High Jungle of Northern Peru. *PLoS Negl Trop Dis* **9**, e0003779 (2015).
699 23. J. D. Ramirez, C. Hernandez, Trypanosoma cruzi I: Towards the need of genetic
700 subdivision?, Part II. *Acta Trop* **184**, 53-58 (2018).
701 24. T. Bhattacharyya, N. Murphy, M. A. Miles, Diversity of Chagas disease diagnostic
702 antigens: Successes and limitations. *PLOS Neglected Tropical Diseases* **18**, e0012512
703 (2024).
704 25. G. Cooley, R. D. Etheridge, C. Boehlke, B. Bundy, D. B. Weatherly, T. Minning, M.
705 Haney, M. Postan, S. Laucella, R. L. Tarleton, High throughput selection of effective
706 serodiagnostics for Trypanosoma cruzi infection. *PLoS Negl Trop Dis* **2**, e316 (2008).
707 26. A. D. Ricci, L. Bracco, E. Salas-Sarduy, J. M. Ramsey, M. S. Nolan, M. K. Lynn, J.
708 Altcheh, G. E. Ballering, F. Torrico, N. Kesper, J. C. Villar, I. S. Marcipar, J. D. Marco,
709 F. Aguero, The Trypanosoma cruzi Antigen and Epitope Atlas: antibody specificities in
710 Chagas disease patients across the Americas. *Nat Commun* **14**, 1850 (2023).
711 27. A. Majeau, E. Dumonteil, C. Herrera, Identification of highly conserved Trypanosoma
712 cruzi antigens for the development of a universal serological diagnostic assay. *Emerg*
713 *Microbes Infect* **13**, 2315964 (2024).
714 28. D. Mohan, D. L. Wansley, B. M. Sie, M. S. Noon, A. N. Baer, U. Laserson, H. B.
715 Larman, PhIP-Seq characterization of serum antibodies using oligonucleotide-encoded
716 peptidomes. *Nat Protoc* **13**, 1958-1978 (2018).

717 29. J. A. Atwood, 3rd, D. B. Weatherly, T. A. Minning, B. Bundy, C. Cavola, F. R.
718 Opperdoes, R. Orlando, R. L. Tarleton, The Trypanosoma cruzi proteome. *Science* **309**,
719 473-476 (2005).
720 30. C. F. Ibanez, J. L. Affranchino, A. C. Frasch, Antigenic determinants of Trypanosoma
721 cruzi defined by cloning of parasite DNA. *Mol Biochem Parasitol* **25**, 175-184 (1987).
722 31. C. F. Ibanez, J. L. Affranchino, R. A. Macina, M. B. Reyes, S. Leguizamon, M. E.
723 Camargo, L. Aslund, U. Pettersson, A. C. Frasch, Multiple Trypanosoma cruzi antigens
724 containing tandemly repeated amino acid sequence motifs. *Mol Biochem Parasitol* **30**,
725 27-33 (1988).
726 32. R. L. Houghton, D. R. Benson, L. D. Reynolds, P. D. McNeill, P. R. Sleath, M. J. Lodes,
727 Y. A. Skeiky, D. A. Leiby, R. Badaro, S. G. Reed, A multi-epitope synthetic peptide and
728 recombinant protein for the detection of antibodies to Trypanosoma cruzi in
729 radioimmunoprecipitation-confirmed and consensus-positive sera. *J Infect Dis* **179**, 1226-
730 1234 (1999).
731 33. A. Majeau, L. Murphy, C. Herrera, E. Dumonteil, Assessing Trypanosoma cruzi Parasite
732 Diversity through Comparative Genomics: Implications for Disease Epidemiology and
733 Diagnostics. *Pathogens* **10**, (2021).
734 34. R. L. Houghton, Y. Y. Stevens, K. Hjerrild, J. Guderian, M. Okamoto, M. Kabir, S. G.
735 Reed, D. A. Leiby, W. J. Morrow, M. Lorca, S. Raychaudhuri, Lateral flow immunoassay
736 for diagnosis of Trypanosoma cruzi infection with high correlation to the
737 radioimmunoprecipitation assay. *Clin Vaccine Immunol* **16**, 515-520 (2009).
738 35. Wiener Lab Group. (2004), vol. 2020.
739 36. T. L. Bailey, C. Elkan, Fitting a mixture model by expectation maximization to discover
740 motifs in biopolymers. *Proc Int Conf Intell Syst Mol Biol* **2**, 28-36 (1994).
741 37. C. E. Grant, T. L. Bailey, W. S. Noble, FIMO: scanning for occurrences of a given motif.
742 *Bioinformatics* **27**, 1017-1018 (2011).
743 38. K. K. Stimpert, S. P. Montgomery, Physician awareness of Chagas disease, USA. *Emerg*
744 *Infect Dis* **16**, 871-872 (2010).
745 39. E. A. Kelly, J. I. Echeverri Alegre, K. Promer, J. Hayon, R. Iordanov, K. Rangwalla, J. J.
746 Zhang, Z. Fang, C. Huang, C. E. Bittencourt, S. Reed, R. M. Andrade, C. Bern, E. H.
747 Clark, J. D. Whitman, Chagas Disease Diagnostic Practices at Four Major Hospital
748 Systems in California and Texas. *J Infect Dis* **229**, 198-202 (2024).
749 40. E. E. Okamoto, J. E. Sherbuk, E. H. Clark, M. A. Marks, O. Gandarilla, G. Galdos-
750 Cardenas, A. Vasquez-Villar, J. Choi, T. C. Crawford, R. Q. Do, A. B. Fernandez, R.
751 Colanzi, J. L. Flores-Franco, R. H. Gilman, C. Bern, B. Chagas Disease Working Group
752 in, Peru, Biomarkers in Trypanosoma cruzi-infected and uninfected individuals with
753 varying severity of cardiomyopathy in Santa Cruz, Bolivia. *PLoS Negl Trop Dis* **8**, e3227
754 (2014).
755 41. D. F. Hoft, K. S. Kim, K. Otsu, D. R. Moser, W. J. Yost, J. H. Blumin, J. E. Donelson, L.
756 V. Kirchhoff, Trypanosoma cruzi expresses diverse repetitive protein antigens. *Infect*
757 *Immun* **57**, 1959-1967 (1989).
758 42. C. A. Buscaglia, O. Campetella, M. S. Leguizamon, A. C. Frasch, The repetitive domain
759 of Trypanosoma cruzi trans-sialidase enhances the immune response against the catalytic
760 domain. *J Infect Dis* **177**, 431-436 (1998).

761 43. A. F. Nardy, C. G. Freire-de-Lima, A. R. Perez, A. Morrot, Role of Trypanosoma cruzi
762 Trans-sialidase on the Escape from Host Immune Surveillance. *Front Microbiol* **7**, 348
763 (2016).
764 44. J. L. Affranchino, C. F. Ibanez, A. O. Luquetti, A. Rassi, M. B. Reyes, R. A. Macina, L.
765 Aslund, U. Pettersson, A. C. Frasch, Identification of a Trypanosoma cruzi antigen that is
766 shed during the acute phase of Chagas' disease. *Mol Biochem Parasitol* **34**, 221-228
767 (1989).
768 45. N. Murphy, B. Rooney, T. Bhattacharyya, O. Triana-Chavez, A. Krueger, S. M. Haslam,
769 V. O'Rourke, M. Panczuk, J. Tsang, J. Bickford-Smith, R. H. Gilman, K. Tetteh, C.
770 Drakeley, C. M. Smales, M. A. Miles, Glycosylation of Trypanosoma cruzi TcI antigen
771 reveals recognition by chagasic sera. *Sci Rep* **10**, 16395 (2020).
772 46. N. M. El-Sayed, P. J. Myler, D. C. Bartholomeu, D. Nilsson, G. Aggarwal, A. N. Tran, E.
773 Ghedin, E. A. Worthey, A. L. Delcher, G. Blandin, S. J. Westenberger, E. Caler, G. C.
774 Cerqueira, C. Branche, B. Haas, A. Anupama, E. Arner, L. Aslund, P. Attipoe, E.
775 Bontempi, F. Bringaud, P. Burton, E. Cadag, D. A. Campbell, M. Carrington, J. Crabtree,
776 H. Darban, J. F. da Silveira, P. de Jong, K. Edwards, P. T. Englund, G. Fazelina, T.
777 Feldblyum, M. Ferella, A. C. Frasch, K. Gull, D. Horn, L. Hou, Y. Huang, E. Kindlund,
778 M. Klingbeil, S. Kluge, H. Koo, D. Lacerda, M. J. Levin, H. Lorenzi, T. Louie, C. R.
779 Machado, R. McCulloch, A. McKenna, Y. Mizuno, J. C. Mottram, S. Nelson, S. Ochaya,
780 K. Osoegawa, G. Pai, M. Parsons, M. Pentony, U. Pettersson, M. Pop, J. L. Ramirez, J.
781 Rinta, L. Robertson, S. L. Salzberg, D. O. Sanchez, A. Seyler, R. Sharma, J. Shetty, A. J.
782 Simpson, E. Sisk, M. T. Tammi, R. Tarleton, S. Teixeira, S. Van Aken, C. Vogt, P. N.
783 Ward, B. Wickstead, J. Wortman, O. White, C. M. Fraser, K. D. Stuart, B. Andersson,
784 The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. *Science*
785 **309**, 409-415 (2005).
786 47. J. V. Rajan, M. McCracken, C. Mandel-Brehm, G. Gromowski, S. Pollett, R. Jarman, J.
787 L. DeRisi, Phage display demonstrates durable differences in serological profile by route
788 of inoculation in primary infections of non-human primates with Dengue Virus 1. *Sci Rep*
789 **11**, 10823 (2021).
790 48. W. Li, A. Godzik, Cd-hit: a fast program for clustering and comparing large sets of
791 protein or nucleotide sequences. *Bioinformatics* **22**, 1658-1659 (2006).
792 49. L. Fu, B. Niu, Z. Zhu, S. Wu, W. Li, CD-HIT: accelerated for clustering the next-
793 generation sequencing data. *Bioinformatics* **28**, 3150-3152 (2012).
794 50. M. Dysinger, L. E. King, Practical quantitative and kinetic applications of bio-layer
795 interferometry for toxicokinetic analysis of a monoclonal antibody therapeutic. *J*
796 *Immunol Methods* **379**, 30-41 (2012).

797

798 **Acknowledgments:** We thank members of the DeRisi Lab for helpful discussions during these
799 studies. We also acknowledge the New York Blood Center for contribution of healthy
800 control plasma. Contents herein are the sole responsibility of the authors and do not
801 necessarily represent the official views of the NIH or other funding agencies.

802 **Funding:**

803 Chan Zuckerberg Biohub (JLD)

804 Chan Zuckerberg Biohub Physician-Scientist Fellowship Program (JDW)

National Heart Lung and Blood Institute award K38HL154203 (JDW)

**Author contributions:**

Conceptualization: JLD, JDW, CB, JVR

Methodology: JDW, JLD, CB, JVR, HMK, RJM, EDG, NLB, JJP, WW, RLT, SLS, EEO, JES, EHC, RHG, RC

Investigation: HMK, RJM, JDW, JVR, AM, NLB, GW, AM, AS, CJF, EAK, ET

Formal analysis: HMK, RJM, JVR

Visualization: HMK, RJM, JDW, JVR

Funding acquisition: JLD, JDW

Project administration: JDW, JLD

Supervision: JDW, JLD, CB, EDG

Writing – original draft: JDW, HMK, RJM

Writing – review & editing: All co-authors

**Competing interests:** JDW is a medical consultant for MelioLabs Inc. RJM is an employee of Agilent Technologies. HMK, RJM, JDW, CB, JVR, and JLD are inventors on a provisional patent application by the Regents of the University of California and the Chan Zuckerberg Biohub San Francisco that covers peptide antigens related to TS-2.23. The other authors declare that they have no competing interests.

**Data and materials availability:** All raw and processed data will be available for download on Dryad. PhIP-seq analytical code will be available at https://github.com/hkortbawi.